Previous 10 | Next 10 |
2023-05-04 10:08:25 ET BridgeBio Pharma press release ( NASDAQ: BBIO ): Q1 GAAP EPS of -$0.92. Revenue of $1.83M (+8.3% Y/Y). For further details see: BridgeBio Pharma GAAP EPS of -$0.92, revenue of $1.83M
- Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) has now completed last patient last visit and remains on track for topline month 30 registrational data to be announced in late July 2023 - Positive results announced in Cohort 5...
PALO ALTO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will pr...
2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...
2023-04-19 09:35:00 ET Evercore ISI has initiated coverage of BridgeBio Pharma ( NASDAQ: BBIO ) with an outperform rating saying that two of its candidates are "potential blockbusters." The firm has a $40 price target (~164% upside based on Tuesday's close). Shares are...
2023-04-19 08:38:04 ET Intuitive Machines ( LUNR ) +24% up 24% as JV with KBR bags a $719M NASA contract. VYNE Therapeutics ( VYNE ) +21% a nnounces positive Preclinical data for inhaled formulation of VYN201 in an in Vivo model of idiopathic pulmonary fibrosis...
2023-04-10 16:03:39 ET BridgeBio Pharma ( NASDAQ: BBIO ), a drug developer targeting genetic diseases, lost ~4% on Monday after a few leading members of its management team, including its chief executive, sold more than $2M worth of company shares. According to two separat...
2023-04-03 10:00:00 ET Growth stocks may have struggled over the past year, but a select few names have defied this broad downward trend in growth equities. Within healthcare, pharma companies developing cutting-edge medicines have been a particular bright spot. Several companies with n...
2023-04-02 16:32:28 ET Apellis Pharmaceuticals ( NASDAQ: APLS ) has attracted takeover interest from large pharmaceutical companies. The biotech firm that's focused on rare diseases and opthalmology is talking to advisers to consider its options, according to a ...
2023-03-29 12:12:50 ET BridgeBio Pharma ( NASDAQ: BBIO ), a potential buyout target, added ~18% on Wednesday, recording the second-best intraday gain for the year, amid market rumors that the company has decided to pull out of a conference next week. BridgeBio ( BBIO...
News, Short Squeeze, Breakout and More Instantly...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...